Resumo

SANCHEZ JIMENEZ, FJ; LOPEZ HONDUVILLA, FJ; APARICIO HERNANDEZ, R  e  GARCIA LUQUE, A. Possitive assessment of drugs: june/july 2017. Sanid. Mil. [online]. 2017, vol.73, n.4, pp.226-230. ISSN 1887-8571.  https://dx.doi.org/10.4321/s1887-85712017000400005.

The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in, June1 and July 20172, considered of interest to the healthcare professional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

Palavras-chave : Adalimumab (Imraldi^®); Atezolizumab (Tecentriq^®); Avelumab (Bavencio^®); Ciclosporina (Verkazia^®); Cladribina (Mavenclad^®): Darunavir/Cobicistat/Emtricitabina/ Tenofovir Alafenamida (Symtuza^®); Dupilumab (Dupixent^®); Glecaprevir/Pibrentasvir (Maviret^®): Lutecio (¹⁷⁷lu) Oxodotreotido (Lutathera^®); Midostaurina (Rydapt^®); Ribociclib (Kisqal^®); Sofosbuvir/Velpatasvir/ Voxilaprevir (Vosevi^®); Telotristat de Etilo (Xermelo^®); Tivozanib Hidrocloruro Monohidrato (Fotivda^®).

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )